Nevertheless, a limitation of the aforementioned agonistantagonist comparison studies is the fact that they were conducted in anesthetized and not awake animals, which might not reflect the behavior of these agonist radiotracers in conscious human studies. This issue was raised in an ex vivo rat study in which the amphetamine-induced displacement of the agonist radiotracers [
11 C]PHNO and [ 11 C]NPA was no different from that observed for the antagonist radiotracer [
11 C]raclopride under unanesthetized conditions (McCormick et al., 2008) . Also consistent with this observation is a nonhuman primate PET study in which methamphetamine-induced displacement of the agonist [
11 C]2-methoxy-N-propyl-norapomorphine was significantly greater in the anesthetized as opposed to the awake condition (Ohba et al., 2009 ). However, both of these studies had methodological issues that complicate the interpretation of their results. For example, the ex vivo rodent study administered nontracer doses of [ 11 C]PHNO and evaluated the amphetamine-induced displacement only at a single time point. These factors may have led to a lower displacement of the agonist after amphetamine and thereby affected the agonist-antagonist comparison. In the nonhuman primate study, no parallel evaluations of amphetamine-induced displacement of a D 2 antagonist radiotracer were performed in the same animals under awake and anesthetized conditions. Thus, a true comparison of the agonist and antagonist displacements in the same animals under both the anesthetized and awake conditions was not provided. Despite the limitations these results raise the possibility that D 2 agonist radiotracers may not offer any significant advantage over D 2 antagonist radiotracers in the study of amphetamine-induced dopamine transmission under unanesthetized conditions. This has important implications for the use of D 2 agonist radiotracers in human research, which is almost always conducted in conscious subjects.
To date only one published study has evaluated the displacement of a D 2 agonist radiotracer after amphetamine challenge in humans (Willeit et al., 2008) . In this study, the D 2 agonist radiotracer [ 11 C]PHNO was displaceable in the caudate (Ϫ13.2%), putamen (Ϫ20.8%), and ventral striatum (Ϫ24.9%) but not globus pallidus (Ϫ6.5%) after the administration of 0.5 mg ⅐ kg Ϫ1 oral amphetamine. Because this study did not measure the magnitude of displacement of the D 2 antagonist radiotracer [
11 C]raclopride in the same subjects, it was not possible to ascertain from this data set whether D 2 agonist radiotracers are superior tools to measure amphetamine-induced dopamine release in humans. To address this question we evaluated the in vivo binding characteristics of the D 2 agonist radiotracer [ 11 C]NPA and the reference antagonist radiotracer [
11 C]raclopride in the same healthy human subjects before and after an acute amphetamine challenge.
Materials and Methods
General Design. The study was approved by the Institutional Review Board of the University of Pittsburgh. In total, 40 PET scans were acquired for this study in 10 healthy control subjects over 20 experimental sessions. Each experimental session included two PET scans: a baseline scan and a postamphetamine scan with the same radiotracer. All subjects returned for a second experimental session in a minimum of 1 week (but no longer than 3 weeks) identical to the first, but with the other radiotracer (a total of four scans per subject).
The sequence of the radiotracers was counterbalanced across subjects to prevent bias in the between-radiotracer comparison. Five subjects received [ 11 C]raclorpide scans during the first experimental session and the remaining five received [ 11 C]NPA scans during the first experimental session. The postamphetamine scan occurred 3 h after the administration of 0.5 mg ⅐ kg Ϫ1 oral d-amphetamine. PET Protocol. The radiolabeling of [ 11 C]NPA and [ 11 C]raclopride was performed by using previously published procedures (Halldin et al., 1991; Hwang et al., 2000) . PET outcome measures described in the article are consistent with the recommended consensus nomenclature for in vivo imaging of reversibly binding radioligands (Innis et al., 2007) .
Imaging experiments were conducted on an ECAT EXACT HRϩ camera (Siemens, Knoxville, TN) consistent with previously described image acquisition protocols (Narendran et al., 2009a) . In brief, after completion of a transmission scan (ϳ10 min) for attenuation correction of the emission data, subjects received either an intravenous injection of [ 11 C]raclopride or [ 11 C]NPA as a bolus over 20 s. Based on previous reports, the maximal injected mass for [ 11 C]raclopride and [ 11 C]NPA was restricted to 6 and 2 g, respectively (Mawlawi et al., 2001; Narendran et al., 2009a ) to be at tracer dose (less than 5% receptor occupancy). Emission data were collected for 60 min. The postamphetamine scan was performed 3 h after the administration of 0.5 mg ⅐ kg Ϫ1 oral amphetamine. Input Function Measurement. After radiotracer injection, arterial samples were collected manually approximately every 6 s for the first 2 min and thereafter at longer intervals. In total, 35 samples were obtained per scan. After centrifugation, plasma was collected in 200-l aliquots, and activities were counted in a gamma counter. To determine the plasma activity representing unmetabolized parent compound for [
11 C]raclopride (collected at 8, 12, 20, 30, 40, 50 , and 60 min) and [
11 C]NPA (collected at 4, 8, 12, 16, 20, 40 , and 50 min), seven samples were further processed by using high-performance liquid chromatographic methods described previously for both the radiotracers (Mawlawi et al., 2001; Narendran et al., 2009a) .
For [ 11 C]raclopride, the seven measured parent fractions were fitted by using a sum of two exponentials (Narendran et al., 2004) . For [ 11 C]NPA the parent fractions were fitted to a Hill plot model (Narendran et al., 2009a ). The input function was then calculated as the product of total counts and interpolated parent fraction at each time point. The measured input function values were fitted to a sum of three exponentials from the time of peak plasma activity, and the fitted values were used as the input to the kinetic analysis. The clearance of the parent compound (C L expressed in liters per hour) was calculated as the ratio of the injected dose to the area under the curve of the input function (Abi-Dargham et al., 1994) . The determination of the plasma free fraction (f P ) for both [
11 C]raclopride and [ 11 C]NPA was performed by using ultrafiltration units (Gandelman et al., 1994) .
In the postamphetamine condition, amphetamine plasma levels were measured in three arterial samples obtained at 0, 30, and 60 min relative to the PET scan as described previously (Reimer et al., 1993) . These data ensured that differences in plasma amphetamine concentration did not bias the radiotracer comparison.
Image Analysis. A three-dimensional spoiled gradient recalled sequence magnetic resonance image was acquired by using a Signa 1.5T magnetic resonance imaging scanner (GE Healthcare, Little Chalfont, Buckinghamshire, UK) for coregistration of the PET data. PET data were reconstructed using filtered back-projection and standard corrections applied that included those for photon attenuation, scatter, and radioactive decay. Reconstructed image files were then processed with MEDx image analysis software (Sensor Systems, Inc., Sterling, VA) and SPM2 software (www.fil.ion.ucl.ac.uk/spm). Frame-to-frame motion correction for head movement and magnetic resonance-PET image alignment were performed by using a mutual information algorithm implemented in SPM2 software.
Time-activity curves were generated for the three anatomical subdivisions of the human striatum: ventral striatum (VST), caudate 534 (CAD, which included both the precommissural and postcommissural caudate), and putamen (PUT, which included both precommissural and postcommissural putamen) using criteria outlined in Martinez et al. (2003) . In addition, a whole striatum region (STR) was derived as the weighted average of the VST, CAD, and PUT. The cerebellum was subsampled in 15 consecutive coronal magnetic resonance imaging slices caudal to the cerebellar peduncle and used as a reference region using previously described methods (Narendran et al., 2009b) .
For bilateral regions, right and left values were averaged. The contribution of plasma total activity to the regional activity was calculated by assuming a 5% blood volume in the regions of interest (Mintun et al., 1984) , and tissue activities were calculated as the total regional activities minus the plasma contribution.
Derivation of Radiotracer Binding Parameters. The three outcome measures provided are reference tissue distribution volume (V ND , milliliters per cubic centimeter), regions of interest binding potential relative to plasma concentration (BP P , milliliters per cubic centimeter), and binding potential relative to nonspecific uptake (BP ND , unitless). The definitions of these outcome measures are outlined in Innis et al. (2007) .
The amphetamine-induced change in BP ND was calculated as the difference between BP ND measured in the postamphetamine condition (BP ND AMPH ) and BP ND measured in the baseline condition on that day (BP ND BASE ) and is expressed as a percentage of BP ND BASE :
⌬BP ND is generally preferred to ⌬BP P (which is derived using eq. 1 and substituting BP P for BP ND ) in clinical studies to measure the effect of amphetamine, because the test/retest reproducibility of BP ND is typically better than that of BP P . In this article, we include the amphetamine-induced changes in both of these outcome measures. In addition, we report the effect of amphetamine on plasma clearance (C L ), f P , and V ND expressed relative to the preamphetamine value measured the same day.
Derivation of [ 11 C]raclopride and [ 11 C]NPA distribution volume (V T ) was performed by using kinetic analysis and the arterial input function. A one-and two-tissue compartment model was used to describe the kinetics in the cerebellum and striatal subdivisions for [ 11 C]raclopride (Lammertsma et al., 1996) . A two-tissue compartment model was used to describe both the cerebellar and striatal kinetics for [ 11 C]NPA (Narendran et al., 2009a) . Statistical Analysis. The effect of amphetamine on the outcome measures was evaluated for each tracer by using repeated measures (RM) ANOVA, with the outcome measure as the dependent variable, the baseline and postamphetamine conditions as the repeated condition, and the region as the cofactor (n ϭ 3; VST, CAD, and PUT). The significance levels of the condition and the dose ϫ region interaction are reported. In addition, post hoc comparisons between baseline and postamphetamine conditions in the individual regions of interest were evaluated with paired t tests (n ϭ 4; VST, CAD, PUT, and STR).
When a significant effect of amphetamine was observed for at least one of the two tracers, a second-level analysis was performed to test for between-tracer difference in this amphetamine effect. This evaluation was performed by using RM ANOVA, with the amphetamine effect on the outcome measure as the dependent variable (⌬BP ND or ⌬BP P ), the tracer as the repeated condition, and the region as the cofactor. The significance levels of the tracer condition and the region ϫ condition interaction are reported. A two-tailed p ϭ 0.05 was selected as the significance level all statistical tests.
Results

Demographics
Ten subjects (two males and eight females; one African American and nine whites) participated in the study. The mean age of the subjects was 28 Ϯ 9 years (range, 19 -50). All 10 subjects who participated in the study were nonsmokers.
Baseline Scan Parameters: Injected Dose and Mass
The mean injected dose, mass, and specific activity at the time of injection for the baseline and postamphetamine condition for radiotracers (Table 1) . Amphetamine Plasma Levels. No significant differences in the amphetamine plasma levels were observed between the postamphetamine [ 11 C]raclopride and [ 11 C]NPA scans (RM ANOVA, p ϭ 0.20). The amphetamine plasma levels were relatively stable throughout the duration of the postamphetamine scan for both radioligands (Table 1) .
Regions of Interest Volumes
The mean volumes of the ventral striatum, caudate, and putamen were 2039 Ϯ 582, 5535 Ϯ 514, and 8337 Ϯ 851 mm 3 .
TABLE 1
Baseline scan parameters and plasma analysis (n ϭ 10 subjects) The mean volumes of the whole striatum and subsampled cerebellum were 15,912 Ϯ 1313 and 20,397 Ϯ 3071 mm 3 . Amphetamine produced a statistically significant decrease in [
Reference Region Analysis
11 C]raclopride BP ND in the striatal subdivisions (RM ANOVA, ⌬BP ND as dependent variable; tracer factor, p ϭ 0.004; tracer ϫ region interaction, p Ͻ 0.001).
Amphetamine produced a statistically significant decrease in [
11 C]NPA BP ND in the striatal subdivisions (RM ANOVA, ⌬BP ND as dependent variable; tracer factor, p Ͻ 0.001; tracer ϫ region interaction, p ϭ 0.004).
When both radiotracers were included in the analysis, the amphetamine-induced change in [ 11 C]NPA ⌬BP ND was significantly higher than [ 11 C]raclopride ⌬BP ND (RM ANOVA, ⌬BP ND as dependent variable; tracer factor, p ϭ 0.003; tracer ϫ region interaction, p ϭ 0.80). 11 C]raclopride BP P in the striatal subdivisions (RM ANOVA, ⌬BP P as dependent variable; tracer factor, p ϭ 0.024; tracer ϫ region interaction, p Ͻ 0.001).
Region of Interest Analysis: Binding Potential BP P
11 C]NPA BP P in the striatal subdivisions (RM ANOVA, ⌬BP P as dependent variable; tracer factor, p ϭ 0.049; tracer ϫ region interaction, p ϭ 0.011).
When both radiotracers were included in the analysis, the amphetamine-induced change in [
11 C]NPA ⌬BP P was not significantly higher than [
11 C]raclopride ⌬BP P (RM ANOVA, ⌬BP ND as dependent variable; tracer factor, p ϭ 0.50).
Amphetamine-induced decreases in [ 11 C]raclopride or [ 11 C]NPA BP P and BP ND in the striatal regions of interest were not significantly correlated with the plasma amphetamine levels achieved during the scan (Pearson correlation coefficient, p Ͼ 0.05). In addition, the order of the sequence (first or second) in which subjects received the radiotracer had no significant effect on amphetamine-induced reduction in BP ND or BP P for [ 
Discussion
The data from this comparison study raise two relevant questions regarding D 2 agonist radiotracers.
Are D 2 Agonist Radiotracers Superior Tools to Measure Amphetamine-Induced DA Release in Humans? The primary objective of this study was to compare the effect of amphetamine on [
11 C]raclopride and [ 11 C]NPA in vivo specific binding in healthy human subjects. This was under- Tsukada et al., 2000; McCormick et al., 2008; Ohba et al., 2009 ). Thus, we performed the above-mentioned experiments in the same human subjects under carefully controlled conditions and in a counterbalanced sequence. Unfortunately, the results of this study did not allow for definitive conclusions to be drawn for or against the superiority of D 2 agonist radiotracers to measure dopamine transmission. Under the experimental conditions of this study, the amphetamine-induced increase in synaptic dopamine in the striatal subdivisions resulted in a 49 to 90% larger decrease in [ 11 C]NPA BP ND compared with [
11 C]raclopride BP ND . Consistent with this result was the comparison of ⌬BP P for these radioligands, which suggested a 14 to 23% larger decrease for [ 11 C]NPA BP P relative to [
11 C]raclopride BP P ; however, this decrease was not statistically significant. The discordance between significance level of the findings for BP ND and BP P was caused by the reduction in [
11 C]raclopride V ND in the cerebellum after the administration of amphetamine. This reduction in V ND led to a poorly correlated ⌬BP ND and ⌬BP P for [
11 C]raclopride. For example, the mean striatal displacement of [
11 C]raclopride after amphetamine was 12% for BP ND and 19% for BP P . In contrast, the amphetamine-induced displacement of [ 11 C]NPA in the striatum was a nearly identical, Ϫ20 and Ϫ22%, for BP ND and BP P , respectively. A decrease in V ND in a study that evaluates amphetamineinduced dopamine release is a problem because it can underestimate the true effect of amphetamine, more so when ⌬BP ND rather than ⌬BP P is used as an outcome measure. Nevertheless, this issue is rarely discussed in depth in the clinical PET literature in which the measured [ 11 C]raclopride cerebellum V ND is lower more often than not after an acute amphetamine (or methylphenidate) challenge (Table 4) . Thus, a question that is critical to the interpretation of these studies is whether ⌬BP ND or ⌬BP P is the preferred outcome measure for amphetamine-induced DA release studies. BP ND is the ratio of the specific (BP P ) to nondisplaceable (V ND ) distribution volumes at equilibrium (Innis et al., 2007) . Compared with BP P , which is the ratio of specific binding to plasma parent concentration at equilibrium, BP ND is less vulnerable to experimental errors associated with the measurement of the input function and is associated with lower test-retest variability (Mawlawi et al., 2001; Narendran et al., 2009a) . In addition, BP ND can be derived without a plasma input function using reference tissue methods, thereby eliminating the need for an arterial line, which can be uncomfortable for the research volunteers. Thus, ⌬BP ND is typically preferred over ⌬BP P and often reported as the sole outcome measure in clinical PET studies that measure amphetamine-induced DA transmission in humans. Nevertheless, to exclusively ascribe changes in BP ND to changes in receptor parameters (B max / K D ) implies that nondisplaceable free fraction in the brain (f ND , derived as f P /V ND ) is not affected by the experimental factors under study (Innis et al., 2007) , which is a reasonable assumption in a within-subject study design. Similarly, the use of ⌬BP P as defined here implies that f P is invariant (Innis et al., 2007) . In this study, f ND and f P for both the agonist and antagonist radiotracer were unaffected by the administration of amphetamine (Table 1; note that [ 11 C]raclopride f ND ϭ f P /V ND was not affected by amphetamine despite significant change in V ND ), thereby suggesting that both outcome measures BP ND and BP P reflect the changes in B max /K D induced by amphetamine. This is somewhat puzzling given the discrepant results observed with ⌬BP ND and ⌬BP P for [
11 C]raclopride. Nevertheless, these data underscore and argue against the use of a single preferred outcome to report changes in DA release in PET studies.
Another (Table 6 ). This observation is in line with the human test-retest studies that showed a higher variability for [ 11 C]PHNO BP ND (VST, 19 Ϯ 19%; CAD, 9 Ϯ 9%; and PUT, 10 Ϯ 8%; Willeit et al., 2008) relative to [ 11 C]NPA BP ND (VST, 5 Ϯ 5%; CAD, 5 Ϯ 4%; PUT, 6 Ϯ 4%; Narendran et al., 2009a) . Nevertheless, these data showing lower effect sizes to measure DA release for [ 11 C]PHNO relative to [ 11 C]NPA are contradictory to that observed previously in anesthetized cats (Ginovart et al., 2006) and nonhuman primates (Narendran et al., 2004 (Narendran et al., , 2006 . It is likely that some of the advantages of [ 11 C]PHNO over [ 11 C]NPA (such as enhanced preference to bind to D 3 receptors) that led to superior measurement of dopamine transmission in animal studies is partially offset by the relatively poor reproducibility in humans. In the absence of direct comparison studies in humans, the data seem to suggest that [ 11 C]NPA is superior to [ 11 C]PHNO for measuring dopamine release in the striatal subdivisions, despite the fact that the signal-to-noise ratio of [ 11 C]PHNO in the striatum is 2.5-fold higher that that of [ 11 C]NPA (Ginovart et al., 2006; Narendran et al., 2006) .
In summary, we conducted the first comparison study of a dopamine D 2 agonist and antagonist to assess amphetamineinduced dopamine release in healthy human subjects. The results of the study failed to unequivocally demonstrate the superiority of the D 2 agonists over D 2 antagonist radioligands as preferred tools to measure dopamine release because of the nonsignificance of the finding with the BP P outcome measure. Nevertheless, these data add to the growing literature that suggests D 2 agonist radiotracers are more vulnerable to endogenous competition by dopamine than antagonist radiotracers. 
